Isavuconazole for the prophylaxis and treatment of invasive fungal infections in solid organ transplant recipients

Due to immunosuppression and other transplantrelated factors, recipients of solid organ transplants are at risk of invasive fungal disease. Prevention and management of fungal infection in solid organ transplant recipients require knowledge about epidemiology, risk factors, limitations, and advantages of current diagnostic methods that guide treatment. Therapy strategies, both in prophylaxis and treatment, are tailored to different types of transplants based on the effectiveness of various antifungal agents. This review provides insight into the epidemiology, prevention, and management of invasive fungal disease in kidney, pancreas, liver, lung, and heart transplant recipients. New diagnostic techniques and novel therapeutic options improve the management of invasive fungal disease. One of the promising novel therapeutic options is isavuconazole. Isavuconazole belongs to the broad-spectrum second-generation triazole class of drugs and is used to treat invasive aspergillosis and mucormycosis. Compared to other azoles, isavuconazole has several benefits, such as predictable pharmacokinetics, good oral bioavailability and tissue diffusion, and a more favorable safety profile. It also has fewer side effects and a lower potential for drug interactions. These advantages underscore the importance of isavuconazole in therapeutic settings for managing invasive fungal diseases in solid organ transplant recipients. Isavuconazole expands the available antifungal treatment options and is a promising addition to the antifungal armamentarium.